Theravance Biopharma Hits New 52-Week High of $15.34, Up 74.94%

Theravance Biopharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 15.34 on November 3, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a microcap entity with a market capitalization of USD 701 million.
Over the past year, Theravance Biopharma has demonstrated impressive growth, with a remarkable 74.94% increase in stock value, significantly outperforming the S&P 500, which recorded a 19.89% gain during the same period. The company's financial metrics reflect a robust operational performance, highlighted by a substantial 83.75% growth in net sales reported on June 25. Additionally, the operating cash flow reached its highest at USD 245.01 million, and the return on capital employed (ROCE) for the first half of the year stood at 6.23%.

Theravance Biopharma's stock has also shown resilience, with a 52-week low of USD 7.90, indicating a strong recovery trajectory. The company maintains high institutional holdings at 100%, suggesting confidence in its fundamentals. Overall, this milestone marks a noteworthy achievement in Theravance Biopharma's ongoing growth journey.